MétaCan
Menu
Back to cohort
Record W4390114600 · doi:10.3389/fneur.2023.1274194

Predictors of treatment switching in the Big Multiple Sclerosis Data Network

2023· article· en· W4390114600 on OpenAlexafffund
Tim Spelman, Melinda Magyari, Helmut Butzkueven, Anneke van der Walt, Sandra Vukusic, María Trojano, Pietro Iaffaldano, Dana Horáková, Jiří Drahota, Fabio Pellegrini, Robert Hyde, Pierre Duquette, Jeannette Lechner‐Scott, Seyed Aidin Sajedi, Patrice H. Lalive, Vahid Shaygannejad, Serkan Özakbaş, Sara Eichau, Raed Alroughani, Murat Terzi, Marc Girard, Tomáš Kalinčík, François Grand’Maison, Olga Skibina, Samia J. Khoury, Bassem Yamout, María José Sá, Oliver Gerlach, Yolanda Blanco, Rana Karabudak, Celia Oreja‐Guevara, Ayşe Altıntaş, Stella Hughes, Pamela McCombe, Radek Ampapa, Koen de Gans, Chris McGuigan, Aysun Soysal, Julie Prévost, Nevin John, Jihad Inshasi, Leszek Stawiarz, Ali Manouchehrinia, Lars Forsberg, Finn Sellebjerg, Anna Glaser, Luigi Pontieri, Hanna Joensen, Peter Vestergaard Rasmussen, Tobias Sejbæk, Mai Bang Poulsen, Jeppe Romme Christensen, Matthias Kant, Morten Stilund, Henrik Mathiesen, Jan Hillert

Bibliographic record

VenueFrontiers in Neurology · 2023
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsCegep de Saint JeromeUniversité de Montréal
FundersUCB PharmaNational Health and Medical Research CouncilCanadian Institutes of Health ResearchSanofi GenzymeAmicus TherapeuticsGenentechMedDay PharmaceuticalsH. Lundbeck A/SSanofiMultiple Sclerosis International FederationEisaiMultiple Sclerosis AustraliaBiogenVšeobecná Fakultní Nemocnice v PrazeMultiple Sclerosis Society of CanadaAtara BiotherapeuticsUniverzita Karlova v PrazeCelgeneAlexion PharmaceuticalsTeva Pharmaceutical IndustriesBayer HealthCareEuropean CommissionWorld Health OrganizationBristol-Myers Squibb
KeywordsMultiple sclerosisBig dataMedicineComputer scienceData miningPsychiatry

Abstract

fetched live from OpenAlex

Background: Treatment switching is a common challenge and opportunity in real-world clinical practice. Increasing diversity in disease-modifying treatments (DMTs) has generated interest in the identification of reliable and robust predictors of treatment switching across different countries, DMTs, and time periods. Objective: The objective of this retrospective, observational study was to identify independent predictors of treatment switching in a population of relapsing-remitting MS (RRMS) patients in the Big Multiple Sclerosis Data Network of national clinical registries, including the Italian MS registry, the OFSEP of France, the Danish MS registry, the Swedish national MS registry, and the international MSBase Registry. Methods: In this cohort study, we merged information on 269,822 treatment episodes in 110,326 patients from 1997 to 2018 from five clinical registries. Patients were included in the final pooled analysis set if they had initiated at least one DMT during the relapsing-remitting MS (RRMS) stage. Patients not diagnosed with RRMS or RRMS patients not initiating DMT therapy during the RRMS phase were excluded from the analysis. The primary study outcome was treatment switching. A multilevel mixed-effects shared frailty time-to-event model was used to identify independent predictors of treatment switching. The contributing MS registry was included in the pooled analysis as a random effect. Results: Every one-point increase in the Expanded Disability Status Scale (EDSS) score at treatment start was associated with 1.08 times the rate of subsequent switching, adjusting for age, sex, and calendar year (adjusted hazard ratio [aHR] 1.08; 95% CI 1.07-1.08). Women were associated with 1.11 times the rate of switching relative to men (95% CI 1.08-1.14), whilst older age was also associated with an increased rate of treatment switching. DMTs started between 2007 and 2012 were associated with 2.48 times the rate of switching relative to DMTs that began between 1996 and 2006 (aHR 2.48; 95% CI 2.48-2.56). DMTs started from 2013 onwards were more likely to switch relative to the earlier treatment epoch (aHR 8.09; 95% CI 7.79-8.41; reference = 1996-2006). Conclusion: Switching between DMTs is associated with female sex, age, and disability at baseline and has increased in frequency considerably in recent years as more treatment options have become available. Consideration of a patient's individual risk and tolerance profile needs to be taken into account when selecting the most appropriate switch therapy from an expanding array of treatment choices.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.015
metaresearch head score (Gemma)0.036
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.015
Threshold uncertainty score0.077

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0150.036
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0020.006
Science and technology studies0.0010.000
Scholarly communication0.0020.001
Open science0.0010.002
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.141
GPT teacher head0.314
Teacher spread0.173 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations9
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueFrontiers in NeurologySame topicMultiple Sclerosis Research StudiesFrench-language works237,207